FDA Brief

Warning letters Food

FDA warning letter to

Supersmart USA, LLC

LowIssued Jan 21Posted May 5Human Foods Program

FDA says Supersmart USA sold dietary supplements with disease-treatment claims, making them unapproved and misbranded drugs.

What happened

FDA reviewed www.supersmart.com in October 2025 and found it took orders for 11 dietary supplement products. FDA said claims on the website and product labels, such as lowering blood sugar, preventing cardiovascular problems, and relieving arthritis pain, showed the products were intended to treat or prevent disease. FDA also said Super DHA lacked adequate directions because its claimed uses require a licensed practitioner.

What FDA found

  1. Website and label claims, such as lowering blood sugar, preventing cardiovascular problems, and relieving arthritis pain, show the products are intended to treat or prevent disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. Because the products are not generally recognized as safe and effective for those uses, they are unapproved new drugs sold without FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. Super DHA is misbranded because its claimed uses are not suitable for self-diagnosis or treatment without a licensed practitioner, so adequate directions for a layperson cannot be written.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. The company introduced or delivered these products for introduction into interstate commerce.

    sections 301(a) and 301(d) of the Act [21 U.S.C. 331(a), 331(d)]

What FDA wants

Notify FDA in writing within 15 working days of the specific steps taken to address the violations and prevent recurrence, with related documentation. If corrections cannot be completed in 15 working days, state the reason and the time within which they will be done.

Who should pay attention

  • dietary supplement brands sold online
  • companies making blood sugar or heart-health claims
  • retailers and distributors of supplement products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk